By Wayne Koberstein, Executive Editor, Life Science Leader magazine
Follow Me On Twitter @WayneKoberstein
Beyond preclinicals to human trials: a drug that could repair and regrow neurons
NervGen Pharma is a public company in Canada developing drugs to repair nerve damage and neurodegeneration by inhibiting protein tyrosine phosphatase sigma (PTP σ), a key component of the neural-death cascade, to promote nerve regeneration, remyelination, and increased neuroplasticity. Its lead product, coded NVG-291, is a peptide mimetic compound with wide potential for treating numerous neurological conditions. NVG-291 is about to enter a Phase 1 dose-escalation trial prior to planned clinical development for spinal-cord injury, MS, and Alzheimer’s disease.